IL1B and type 2 diabetes mellitus: Metformin, the most widely used first-line agent for T2DM, inhibits caspase-1 and IL-1β production while suppressing cell pyroptosis through AMPK/mTOR signaling, offering cardioprotective effects, particularly against ischemia–reperfusion injury [8,47].